https://www.selleckchem.com/pr....oducts/tbk1-IKKe-in-
Survival in the 2 groups did not differ by Kaplan-Meier analysis (P=.24, and multivariable regression showed no differences in acute rejection (P=.455) or 30-day mortality (P=.49. Of the 326 recipients of NAT hearts, 38 seroconverted and 14 became viremic within 1year. Survival was 100% in the viremic patients and 97.4% in seroconverted patients at 1year. Heart transplantation from HCV viremic donors continues to increase but varies significantly across UNOS regions and individual centers. Short-term outcomes are co